There is an urgent need to find effective
treatment or a vaccine for COVID-19. Worldwide there are over 1,800 trials addressing
COVID-19-related health care. There are 10 trials developed by the US
Department of Veterans Affairs (VA), US Department of Defense, and the
National Institute of Allergy and Infectious Diseases have provided important
data on effective treatment options. The clinical trials listed below are all
open as of May 31, 2020.
Adaptive COVID-19 Treatment Trial (ACTT)
This study is an adaptive, randomized,
double-blind, placebo-controlled trial to evaluate the safety and efficacy of
novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The
study will compare different investigational therapeutic agents to a control
arm. ID: NCT04280705
Study to Evaluate the Safety and
Antiviral Activity of Remdesivir (GS-5734) in Participants with Severe
Coronavirus Disease (COVID-19)
The primary objective of this study is to
evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical
status assessed by a 7-point ordinal scale on Day 11 (NCT04292730) or Day 14
(NCT04292899).
Expanded Access Remdesivir (RDV; GS-5734)
The treatment of communicable Novel
Coronavirus of 2019 with Remdesivir (RDV; GS-5734) also known as severe acute
respiratory syndrome coronavirus 2.
A Study to Evaluate the Safety and Efficacy
of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA)
This study will evaluate the efficacy,
safety, pharmacodynamics, and pharmacokinetics of tocilizumab compared with a matching placebo in combination
with standard of care in hospitalized patients with severe COVID-19 pneumonia.
Administration of Intravenous Vitamin C
in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation (AVoCaDO)
The study evaluates if Vit C is safe and
tolerable in COVID-19 subjects given early or late in the disease course and may
reduce the risk of respiratory failure requiring mechanical ventilation and
development of ARDS along with reductions in supplemental oxygen demand and
inflammatory markers.
Treatment Of CORONAVIRUS DISEASE 2019
(COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
This is an expanded access open-label,
single-arm, multi-site protocol to provide convalescent plasma as a treatment
for patients diagnosed with severe, or life-threatening COVID-19.
A Study to Evaluate the Safety and
Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe
COVID-19 Pneumonia (COVASTIL)
This is a Phase II, randomized,
double-blind, placebo-controlled, multicenter study to assess the efficacy and
safety of MSTT1041A (astegolimab) or UTTR1147A in combination with standard of
care (SOC) compared with matching placebo in combination with SOC in patients
hospitalized with severe coronavirus disease 2019 pneumonia.
Adaptive COVID-19 Treatment Trial 2
(ACTT-II)
ACTT-II will evaluate the combination of
baricitinib and remdesivir compared to remdesivir alone. Subjects will be
assessed daily while hospitalized. If the subjects are discharged from the
hospital, they will have 3 home visits.
No comments:
Post a Comment